Nutriband Inc. (NTRB)
NasdaqCM
Fundamentals
Valuation and ratings
Nutriband Inc. trades at USD2.99. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
About Nutriband Inc.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
The full research page for NTRB, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.